Abstract:Abstract Introduction: Despite the numerous drugs available for patients with metastatic colorectal cancer (mCRC), median overall survival for this group of patients remains at ~20-24 months, with no significant advances in the last 7 years. In the US ~50,000 patients die each year from mCRC refractory to systemic therapy. Inhibiting angiogenesis as a therapy has led to a great deal of enthusiasm. However, the overall benefit of classical-antiangiogenic therapy remains modest and has not lived up to their expectations in treating CRC. Our recent studies suggest that VEGF intracrine signaling, rather than autocrine/paracrine signaling, regulates cell survival in CRC cells. Further studies to understand the significance and mechanisms of this novel function have led us to identify factors that intracellularly interact with VEGF. Our studies further indicate that one such interacting protein, SPECC1L, may have a significant role in CRC cell proliferation and may be a potential target in mCRC therapy. Methods: Lysates from CRC cells expressing Myc-tagged VEGF protein were immunoprecipitated and analyzed by mass spectrometry to identify VEGF-interacting protiens. SPECC1L was identified as a co-precipitated protein with high level of confidence. SPECC1L was depleted using siRNA and effects of such depletion on CRC cell growth and morphology were measured by cell growth assays (MTT), microscopy, FACS and western blot analyses. Localization of the protein and its interaction with microtubules and actin were visualized by immunostaining of FLAG-tagged recombinant SPECC1L protein. Results: SPECC1L was identified as a protein that co-immunoprecipitated with Myc-tagged VEGF in CRC cells using mass spectroscopy. Previous literature suggests a role for SPECC1L in cell division. As a fraction of VEGF overexpressing CRC cells have a large multinucleated phenotype, likely arising due to defects in cell division, it was hypothesized that a VEGF mediated regulation of SPECC1L may lead to such phenotype. Depletion of SPECC1L by siRNAs in multiple CRC cell lines led to strong defects in cell division. The effects of SPECC1L depletion were manifested as accumulation of doublet-cells failing to complete cytokinesis following mitosis and resulted in reduced cell proliferation. Failure to complete cell division also led to the formation of multinucleated cells and enhanced cell death. Conclusions: Inhibition of SPECC1L strongly inhibits CRC cell proliferation and enhances cell death. Thus targeting SPECC1L has the potential for developing therapeutics that reduce viability of CRC cells and improve survival of colorectal cancer patients. *** These studies were supported by the Gillson-Longenbaugh Foundation. Citation Format: Rajat Bhattacharya, Ling Xia, Fan Fan, Rui Wang, Delphine Boulbes, Xiang-Cang Ye, David Hawke, Lee Ellis. Depletion of SPECC1L inhibits colorectal cancer cell proliferation [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2017; 2017 Apr 1-5; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2017;77(13 Suppl):Abstract nr 3474. doi:10.1158/1538-7445.AM2017-3474

Antitumor Effect of Cycle Inhibiting Factor Expression in Colon Cancer Via Salmonella VNP20009.

Abstract 3474: Depletion of SPECC1L Inhibits Colorectal Cancer Cell Proliferation

Modulation of Salmonella Tumor-Colonization and Intratumoral Anti-angiogenesis by Triptolide and Its Mechanism.

FH535 Inhibits Proliferation and Motility of Colon Cancer Cells by Targeting Wnt/β-catenin Signaling Pathway

Suppression of cellular apoptosis susceptibility (CSE1L) inhibits proliferation and induces apoptosis in colorectal cancer cells.

Synergistic Antitumor Effects of Cmet Inhibitor in Combination with Anti-Vegf in Colorectal Cancer Patient-Derived Xenograft Models

Cytotoxic necrotizing factor 1 hinders colon tumorigenesis induced by colibactin-producing Escherichia coli in ApcMin/+ mice

Tumor-specific cell-cycle decoy by Salmonella typhimurium A1-R combined with tumor-selective cell-cycle trap by methioninase overcome tumor intrinsic chemoresistance as visualized by FUCCI imaging

Salmonella-Mediated Cytolethal Distending Toxin Transfer Inhibits Tumor Growth

Reversible senescence of human colon cancer cells after blockage of mitosis/cytokinesis caused by the CNF1 cyclomodulin from Escherichia coli

Proteomic Screening of Anaerobically Regulated Promoters from Salmonella and Its Antitumor Applications.

CSBF/C10orf99, a novel potential cytokine, inhibits colon cancer cell growth through inducing G1 arrest

Silibinin Retards Colitis-associated Carcinogenesis by Repression of Cdc25C in Mouse Model

Sini Decoction Inhibits Tumor Progression and Enhances the Anti-Tumor Immune Response in a Murine Model of Colon Cancer

Curcumin Suppresses Colon Cancer in Vitro and in Vivo

Oral Delivery of Tumor‐targeting Salmonella Exhibits Promising Therapeutic Efficacy and Low Toxicity

Interferon induced transmembrane protein 1 with interferon α synergistically inhibited proliferation of colorectal cancer cell line SW480

Fine-tuning Bacterial Cyclic di-AMP Production for Durable Antitumor Effects Through the Activation of the STING Pathway

IFN-γ enhances the antitumor activity of attenuated salmonella-mediated cancer immunotherapy by increasing M1 macrophage and CD4 and CD8 T cell counts and decreasing neutrophil counts

Combination of VP3 and CD147-knockdown enhance apoptosis and tumor growth delay index in colorectal tumor allograft

Antibacterial Fusobacterium Nucleatum‐Mimicking Nanomedicine to Selectively Eliminate Tumor‐colonized Bacteria And Enhance Immunotherapy Against Colorectal Cancer